Cargando…
Salvage Brachytherapy for Biochemically Recurrent Prostate Cancer following Primary Brachytherapy
Purpose. In this study, we evaluated our experience with salvage brachytherapy after discovery of biochemical recurrence after a prior brachytherapy procedure. Methods and Materials. From 2001 through 2012 twenty-one patients treated by brachytherapy within University of Kentucky or from outside cen...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4820628/ https://www.ncbi.nlm.nih.gov/pubmed/27092279 http://dx.doi.org/10.1155/2016/9561494 |
_version_ | 1782425441217282048 |
---|---|
author | Lacy, John M. Wilson, William A. Bole, Raevti Chen, Li Meigooni, Ali S. Rowland, Randall G. Clair, William H. St. |
author_facet | Lacy, John M. Wilson, William A. Bole, Raevti Chen, Li Meigooni, Ali S. Rowland, Randall G. Clair, William H. St. |
author_sort | Lacy, John M. |
collection | PubMed |
description | Purpose. In this study, we evaluated our experience with salvage brachytherapy after discovery of biochemical recurrence after a prior brachytherapy procedure. Methods and Materials. From 2001 through 2012 twenty-one patients treated by brachytherapy within University of Kentucky or from outside centers developed biochemical failure and had no evidence of metastases. Computed tomography (CT) scans were evaluated; patients who had an underseeded portion of their prostate were considered for reimplantation. Results. The majority of the patients in this study (61.9%) were low risk and median presalvage PSA was 3.49 (range 17.41–1.68). Mean follow-up was 61 months. At last follow-up after reseeding, 11/21 (52.4%) were free of biochemical recurrence. There was a trend towards decreased freedom from biochemical recurrence in low risk patients (p = 0.12). International Prostate Symptom Scores (IPSS) increased at 3-month follow-up visits but decreased and were equivalent to baseline scores at 18 months. Conclusions. Salvage brachytherapy after primary brachytherapy is possible; however, in our experience the side-effect profile after the second brachytherapy procedure was higher than after the first brachytherapy procedure. In this cohort of patients we demonstrate that approximately 50% oncologic control, low risk patients appear to have better outcomes than others. |
format | Online Article Text |
id | pubmed-4820628 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-48206282016-04-18 Salvage Brachytherapy for Biochemically Recurrent Prostate Cancer following Primary Brachytherapy Lacy, John M. Wilson, William A. Bole, Raevti Chen, Li Meigooni, Ali S. Rowland, Randall G. Clair, William H. St. Prostate Cancer Research Article Purpose. In this study, we evaluated our experience with salvage brachytherapy after discovery of biochemical recurrence after a prior brachytherapy procedure. Methods and Materials. From 2001 through 2012 twenty-one patients treated by brachytherapy within University of Kentucky or from outside centers developed biochemical failure and had no evidence of metastases. Computed tomography (CT) scans were evaluated; patients who had an underseeded portion of their prostate were considered for reimplantation. Results. The majority of the patients in this study (61.9%) were low risk and median presalvage PSA was 3.49 (range 17.41–1.68). Mean follow-up was 61 months. At last follow-up after reseeding, 11/21 (52.4%) were free of biochemical recurrence. There was a trend towards decreased freedom from biochemical recurrence in low risk patients (p = 0.12). International Prostate Symptom Scores (IPSS) increased at 3-month follow-up visits but decreased and were equivalent to baseline scores at 18 months. Conclusions. Salvage brachytherapy after primary brachytherapy is possible; however, in our experience the side-effect profile after the second brachytherapy procedure was higher than after the first brachytherapy procedure. In this cohort of patients we demonstrate that approximately 50% oncologic control, low risk patients appear to have better outcomes than others. Hindawi Publishing Corporation 2016 2016-03-22 /pmc/articles/PMC4820628/ /pubmed/27092279 http://dx.doi.org/10.1155/2016/9561494 Text en Copyright © 2016 John M. Lacy et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Lacy, John M. Wilson, William A. Bole, Raevti Chen, Li Meigooni, Ali S. Rowland, Randall G. Clair, William H. St. Salvage Brachytherapy for Biochemically Recurrent Prostate Cancer following Primary Brachytherapy |
title | Salvage Brachytherapy for Biochemically Recurrent Prostate Cancer following Primary Brachytherapy |
title_full | Salvage Brachytherapy for Biochemically Recurrent Prostate Cancer following Primary Brachytherapy |
title_fullStr | Salvage Brachytherapy for Biochemically Recurrent Prostate Cancer following Primary Brachytherapy |
title_full_unstemmed | Salvage Brachytherapy for Biochemically Recurrent Prostate Cancer following Primary Brachytherapy |
title_short | Salvage Brachytherapy for Biochemically Recurrent Prostate Cancer following Primary Brachytherapy |
title_sort | salvage brachytherapy for biochemically recurrent prostate cancer following primary brachytherapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4820628/ https://www.ncbi.nlm.nih.gov/pubmed/27092279 http://dx.doi.org/10.1155/2016/9561494 |
work_keys_str_mv | AT lacyjohnm salvagebrachytherapyforbiochemicallyrecurrentprostatecancerfollowingprimarybrachytherapy AT wilsonwilliama salvagebrachytherapyforbiochemicallyrecurrentprostatecancerfollowingprimarybrachytherapy AT boleraevti salvagebrachytherapyforbiochemicallyrecurrentprostatecancerfollowingprimarybrachytherapy AT chenli salvagebrachytherapyforbiochemicallyrecurrentprostatecancerfollowingprimarybrachytherapy AT meigoonialis salvagebrachytherapyforbiochemicallyrecurrentprostatecancerfollowingprimarybrachytherapy AT rowlandrandallg salvagebrachytherapyforbiochemicallyrecurrentprostatecancerfollowingprimarybrachytherapy AT clairwilliamhst salvagebrachytherapyforbiochemicallyrecurrentprostatecancerfollowingprimarybrachytherapy |